Article Commentary: A Perspective on Transplantation Therapy and Stem Cells for Parkinson's Disease

Freed, William J.

doi:10.3727/000000004783984025

Cited by 23 publications

(11 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Because of the selectivity of the affected cell loss and the focal nature of PD, cell replacement therapy is an attractive option. Clinical investigations of human embryonic neurons and fetal tissue use have led to variable results; some patients have shown improvement (Freed et al, 2001(Freed et al, , 2003Freed, 2004;Hagell et al, 2000;Kordower et al, 1995;Lindvall et al, 1990;Lindvall and Hagell, 2001), while others have exhibited deleterious side effects (Barker, 2002;Freed et al, 2001;Hagell et al, 2002). Further investigation of the efficacy, safety and therapeutic potential of a cell replacement strategy is needed before continuing in the clinical arena.…”

Section: Introductionmentioning

confidence: 95%

A comparison of dopaminergic cells from the human NTera2/D1 cell line transplanted into the hemiparkinsonian rat

Newcomb¹,

Janowski²,

Zigova³

et al. 2007

Life Sciences

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 95%

A comparison of dopaminergic cells from the human NTera2/D1 cell line transplanted into the hemiparkinsonian rat

Newcomb¹,

Janowski²,

Zigova³

et al. 2007

Life Sciences

View full text Add to dashboard Cite

“…However, several factors have been identified that confound interpretation of the negative results of human transplantation trials and require further clarification: surgical technique needs improvement; non-dopaminergic cells within fetal tissue transplants also have been implicated in post-surgical complications [30, 127, 128]. The current mainstream of research is directed at producing a reliable and standardized population of DA-producing cells such as neural progenitor cells (NPC) that can be used for further transplantation trials.…”

Section: Current Trends In Therapeuticsmentioning

confidence: 99%

Targeting the Progression of Parkinsons Disease

George¹,

Mok

Moses

et al. 2009

View full text Add to dashboard Cite

By the time a patient first presents with symptoms of Parkinson’s disease at the clinic, a significant proportion (50-70%) of the cells in the substantia nigra (SN) has already been destroyed. This degeneration progresses until, within a few years, most of the cells have died. Except for rare cases of familial PD, the initial trigger for cell loss is unknown. However, we do have some clues as to why the damage, once initiated, progresses unabated. It would represent a major advance in therapy to arrest cell loss at the stage when the patient first presents at the clinic. Current therapies for Parkinson’s disease focus on relieving the motor symptoms of the disease, these unfortunately lose their effectiveness as the neurodegeneration and symptoms progress. Many experimental approaches are currently being investigated attempting to alter the progression of the disease. These range from replacement of the lost neurons to neuroprotective therapies; each of these will be briefly discussed in this review. The main thrust of this review is to explore the interactions between dopamine, alpha synuclein and redox-active metals. There is abundant evidence suggesting that destruction of SN cells occurs as a result of a self-propagating series of reactions involving dopamine, alpha synuclein and redox-active metals. A potent reducing agent, the neurotransmitter dopamine has a central role in this scheme, acting through redox metallo-chemistry to catalyze the formation of toxic oligomers of alpha-synuclein and neurotoxic metabolites including 6-hydroxydopamine. It has been hypothesized that these feed the cycle of neurodegeneration by generating further oxidative stress. The goal of dissecting and understanding the observed pathological changes is to identify therapeutic targets to mitigate the progression of this debilitating disease.

show abstract

“…In recent years, scientists discovered stem cell like cells in central and peripheral nervous system including olfactory bulb, subventricular zone (SVZ), striate body, cortical layer and spinal cord etc [1] . Pluripotent neural stem cells (NSCs) have become a alternative to repair central lesions, which provides a novel approach for the treatment of nervous system diseases [2] .…”

Section: Discussionmentioning

confidence: 99%

Cloning of the eukaryotic expression vector with nerve growth factor in rats and its effects on proliferation and differentiation of mesencephal neural stem cells of fetal rats

Lin

Yang

et al. 2008

J. Huazhong Univ. Sci. Technol. [Med. Sci.]

View full text Add to dashboard Cite

The eukaryotic expression vector containing full-length cDNA sequence of rate nerve growth factor (NGF) beta subunit was constructed and its effects on proliferation and differentiation of neural stem cells were observed. By using PCR, full-length cDNA sequence of NGF beta subunit in rats was cloned and ligated into the eukaryotic expression vector pEGFP-N1-NGF. The recombinant plasmid pEGFP-N1-NGF was transfected into the mesencephal neural stem cells of embryonic rats by Lipofectamin and transiently expressed. MTT method was used to determine the effects of NGF on proliferation of neural stem cells, and under phase-contrast microscopy, the effects of NGF on growth of nervous processes following differentiation of neural stem cells were observed. Sequence analysis indicated that the cloned full-length cDNA sequence of rat NGF beta was identical to that of published sequence encoding NGF in gene GeneBank. The transfection of recombinant plasmid pEGFP-N1-NGF into mesencephal neural stem cells of embryonic rats could obviously promote proliferation of neural stem cells and facilitate the growth of neural stem cells-derived nerve cells. It was suggested that neural stem cells could be used as a vehicle of gene transfer, and the expression of NGF beta subunit in the neural stem cells could promote the growth of nerve cells derived from neural stem cells.

show abstract

Article Commentary: A Perspective on Transplantation Therapy and Stem Cells for Parkinson's Disease

Cited by 23 publications

References 41 publications

A comparison of dopaminergic cells from the human NTera2/D1 cell line transplanted into the hemiparkinsonian rat

A comparison of dopaminergic cells from the human NTera2/D1 cell line transplanted into the hemiparkinsonian rat

Targeting the Progression of Parkinsons Disease

Cloning of the eukaryotic expression vector with nerve growth factor in rats and its effects on proliferation and differentiation of mesencephal neural stem cells of fetal rats

Contact Info

Product

Resources

About